The commercial real estate needs of life sciences companies (pharma, biotech, medical device) are both varied and complex. While start-ups tend to seek small generic lab space, more established enterprises typically require large build-to-suit spaces in which to house their state-of-the-art production facilities. Similarly diverse are life sciences landlords, who range in size from large REITs to real estate developers and even smaller building owners looking to convert their buildings into lab space in the low vacancy rate areas where such tenants tend to cluster. 

In an earlier post, we explored some of the key issues in a contract manufacturing agreement from the perspective of the drug developer. However, Outside GC frequently represents outsourced manufacturers, too. The knowledge we’ve gained from working on both sides of the table enables us to effectively and efficiently negotiate agreements that satisfy both parties.

Imagine your child or spouse is suffering from an illness with few effective treatment options, such as a rare pediatric cancer or autoimmune disease. Meanwhile, a team of doctors and researchers has been steadily working to unlock the mysteries of this disease for years, in an ongoing effort to identify better solutions for patients.  The team has just published promising results from a recent study in a respected medical journal. The study involved so-called “off-label use” of a prescription drug for these patients, i.e. administering a drug already approved by FDA, on the market, and prescribed by doctors for a related but different medical condition.